Targeted Sequencing Detects Variants That May Contribute to the Risk of Neuropsychiatric Disorders

Jayant Mahadevan1, Reeteka Sud2, Ravi Kumar Nadella1, Pulaparambil Vani1, Anand G. Subramaniam2, Pradip Paul2, Aparna Ganapathy3, Ashraf U. Mannan2, Vijay Chandru3,4, Biju Viswanath1,2, Meera Purushottam2 and Sanjeev Jain1,2

Genetic variants identified with next-generation sequencing (NGS) could help in accurate diagnosis, provide insights into aspects of disease biology,1 and, thus, lead to improved care. Psychiatric symptoms and syndromes overlap with rare genetic disorders associated with intellectual disability (ID)2 and autism spectrum disorders (ASD3) at one end and with neurodegenerative disease4,5 at the other end. These rare variants may be shared within family members.6 Hence, the study of rare variants of moderate-to-large effects becomes important, as they may highlight the dysfunction of disease-associated pathways.

Rare variants associated with disease syndromes may arise de novo and may be related to founder effects, population bottlenecks, genetic drift, or natural selection pressures. Therefore, they also offer insights into the inherent mutability of genes, genetic repair mechanisms, and population diversity.7

We reviewed the records of 11 individuals presenting to the psychiatric services in our hospital, who also underwent targeted sequencing through a genetic analysis service, after informed consent. In general, genetic analysis was requested because of clinical suspicion based on rapid disease progression, atypical disease course, younger age of onset, or significant family history. Specific indications for each case are mentioned in the respective sections.

Case Presentations

Table 1 summarizes the details of each case, gene, and variant identified, and its clinical significance. Details of the methodology used for genotyping and variant prioritization are provided in the supplementary information. We present three cases in greater detail as we felt they represent broad themes pertaining to genotype-phenotype correlation. These are:

1. Both the gene and the variant identified were known genetic causes; identification helped zero down contribution to the patient’s phenotype.
2. Gene identified was known to be related to the patient’s phenotype, but the variant identified was novel, or a new molecular interacting partner(s) of a causative gene was found.
3. Neither the gene nor the variant identified had previously been specifically implicated in the patient’s phenotype but may have biological and heuristic significance.

HOW TO CITE THIS ARTICLE: Mahadevan J, Sud R, Nadella RK, Vani P, Subramaniam AG, Paul P, Ganapathy A, Mannan AU, Chandru V, Viswanath B, Purushottam M and Jain S. Targeted Sequencing Detects Variants That May Contribute to the Risk of Neuropsychiatric Disorders. Indian J Psychol Med. 2022;44(5):516–522.

Address for correspondence: Biju Viswanath, Dept. of Psychiatry, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India. Molecular Genetics Laboratory, Neurobiology Research Centre, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, Karnataka, India. Strand Center for Genomics and Personalized Medicine, Strand Life Sciences, Bengaluru, Karnataka, India. Centre for Biosystems Science and Engineering, Indian Institute of Science, Bengaluru, Karnataka, India.

Submitted: 06 Nov. 2020
Accepted: 18 Jan. 2021
Published Online: 25 Mar. 2021

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://creativecommons.org/licenses/by-nc/4.0/) which permits non-Commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).

ACCESS THIS ARTICLE ONLINE
Website: journals.sagepub.com/home/szj
DOI: 10.1177/0253717621993672
Rare Variant in a Gene Known to Cause Disease: Case A1

Clinical Presentation
A 49-year-old female on treatment for hypothyroidism, working successfully as an executive, presented with behavioral changes in the form of jocularity and disinhibition, and then developed hyperorality, sleep disturbances, restlessness, and repetitive behaviors, over the past 3 years. The initial diagnosis had been a mood disorder, but the symptoms progressed over a few months, with a deterioration of speech and memory. Echolalia, bruxism, and mouthing behavior were observed on examination. A parent and an uncle had been diagnosed with late-onset dementia, and a sibling had similar symptoms. Magnetic resonance imaging showed frontal and anterior temporal lobe atrophy. Frontotemporal dementia (FTD) was diagnosed, and treatment was started with a combination of donepezil (20 mg/day) and trazodone (50 mg/day).

Indication for NGS
Presence of a young-onset, rapid progression of a dementia syndrome, with a significant family history.

Findings From NGS
A likely pathogenic, heterozygous missense variant; c.1853C>T in the gene MAPT (MIM *157140) was detected. The variant leads to the proline residue at position 301 to be substituted with leucine (p.Pro301Leu).

Biological Relevance of Findings
Mutations in the MAPT gene are a known cause of FTD (MIM #600274), and it is one of the three genes responsible for most cases of familial FTD, in addition to C9orf72 and GRN. The specific variant seen in this case has been reported in very few families throughout the world. There is only one other report from Asia documenting this variant, in a Chinese pedigree; but within FTD cases, this mutation is relatively common.

The tau protein molecule can be broadly subdivided into an amino-terminal projection domain, a microtubule-binding domain, and a carboxy-terminal domain. The p.Pro301Leu (P301L) mutation seen in this subject disturbs the conserved PGGG motif within the microtubule-binding domain encoded by exon 10 of the gene. The proline residue at position 301 is critical for the structure of the protein. In vitro functional assessment had shown that this mutation (P301L), in exon 10, has the highest propensity for aggregation than other MAPT mutations. More recent evidence shows that this particular mutation gives rise to multiple diverse pathological conformations of tau protein. Dementia could be a consequence of this process.

New Variant in a Gene Known to Be Associated with the Disease, and Its Plausible Biological Consequences: Case B1

Clinical Presentation
A 19-year-old male presented with insidious onset of symptoms from the age of

| ID | Clinical indication | Gene | Transcript ID | Genomic annotation | cDNA annotation | Protein annotation | Zygosity | dbsNP identified | gnomAD frequency | Count in internal control | Clinical significance/Associated OMIM Syndromes |
|----|-------------------|------|---------------|--------------------|----------------|-------------------|-----------|-----------------|------------------|---------------------------|-------------------------------------------|
| A1 | 49-year-old female with mood symptoms and progressive personality change diagnosed as Fronto-temporal dementia: Family history of similar illness in sister | MAPT | NM_018315.4 | chr7:440 | C>T | p.Pro301Leu | Het | rs63751273 | <0.001 | – | 1. Parkinson's disease, Late Onset; 2. Frontotemporal dementia; 3. Pick's disease; 4. Supranuclear palsy progressive; 5. Parkinson-Desmetia syndrome |
| A2 | 24-year-old female with young onset Parkinson's disease with psychiatric manifestations (delusions and agitation). No family history | PLA2G6 | NM_003560.2 | chr22:3850 | C>T | p.Arg341Gln | Hom | rs121908686 | <0.001 | 6/11400 | 1. Infantile neuroaxonal dystrophy; 2. Neurodegenerative with brain iron accumulation 2B; 3. Autosomal recessive Parkinson's disease 14 |
|    | NOTCH3 | NM_00435.2 | chr9:5328 | C>T | p.Arg232Cys | Het | rs201680145 | 0.001 | 23/3700 | VUS | 1. Cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukencephalopathy, type 1; 2. Infantile fibromatosis 2; 3. Lateral meningoaclue syndrome |

(Table 1 continued)
| ID | Clinical indication                                                                 | Gene | Transcript ID       | Genomic annotation | cDNA annotation | Protein annotation | Zygosity | dbSNP identified | gnomAD frequency | Count in internal control | Clinical significance/Associated OMIM Syndromes                       |
|----|-----------------------------------------------------------------------------------|------|---------------------|--------------------|-----------------|--------------------|----------|-----------------|---------------------|------------------------|------------------------------------------------------------------------|
| A3*| 28-year-old male with adolescent onset of hallucinations, delusions and negative symptoms diagnosed as schizophrenia. Childhood onset progressive proximal muscle weakness suggestive of muscular dystrophy | DMD  | DMD_ NM_004006.2    | Dp10 Dp140         | ChrX            | ex45ex-48del       | null     |                 |                     |                        | LP 1. Becker muscular dystrophy 2. Cardiomyopathy, dilated, 3B 3. Duchenne muscular dystrophy |

**B. New variant in a gene known to be associated with disease, and its biological consequences or treatment**

| ID | Clinical indication                                                                 | Gene | Transcript ID       | Genomic annotation | cDNA annotation | Protein annotation | Zygosity | dbSNP identified | gnomAD frequency | Count in internal control | Clinical significance/Associated OMIM Syndromes                       |
|----|-----------------------------------------------------------------------------------|------|---------------------|--------------------|-----------------|--------------------|----------|-----------------|---------------------|------------------------|------------------------------------------------------------------------|
| B1 | 19-year-old male with childhood ADHD, childhood onset ODD, Cafe-au-lait spots, family history of psychosis in grandmother and major depression in mother | NF1  | NM_000267.3         | chr7: 29508774_29508775del | ITG             | c.701_702delITG    | p.Tyr-235ProfTer6 | Het              | NA                  | NA                    | 1/2>15000                           | LP 1. Leukemia, juvenile myelomeningo-otic 2. Neurofibromatosis-Neonan syndrome 3. Neurofibromatosis, familial spinal 4. Neurofibromatosis, type 1 5. Watson syndrome |
| B2 | 31-year-old male with severe Parkinsonism and renal cysts; No family history     | MAPT | NM_001123.3         | chr17: 440610-440619 | 8gA>G           | c.5267A>G p.His1756Arg | Het      | NA              | NA                  | NA                    | 1/2>3500                           | VUS 1. Parkinson’s Disease, Late Onset; 2. Frontotemporal Dementia; 3. Pick’s Disease; 4. Supranuclear Palsy Progressive; 5. Parkinson-Dementia Syndrome |
| B3 | 56-year-old female with fronto-temporal dementia with Parkinson’s disease; family history of mental illness in mother, brother and younger sister | PARK2| NM_001127.3         | chr17: 133550560   | 8A>G           | c.860A>G p.His287Arg | Het      | NA              | NA                  | NA                    | 1/2>3500                           | VUS 1. Mitochondrial DNA Depletion syndrome 14 2. Behr Syndrome (Early onset Optic atrophy, Spino-cerebellar ataxia, peripheral neuropathy and developmental delay) 3. Dominant Optic Atrophy 4. Dominant Optic Atrophy plus syndrome |
| B4 | 50-year-old female with long standing schizophrenia on treatment; Parkinson’s disease/progressive supranuclear palsy variant later in life. Family history of dementia in father | TENM4| NM_001098.6         | chr11: 7854532    | C>T            | c.532G>A p.Arg177Gln | Het      | NA              | NA                  | NA                    | 1/2>3500                           | VUS Essential tremor, hereditary 5                                             |
### C. Variant(s) in gene(s) not directly implicated in disease but suspected to be of significance, by genetic studies or biological mechanisms

| ID | Clinical indication                                      | Gene     | Transcript ID | Genomic annotation | cDNA annotation | Protein annotation | Zygosity | dbsNP identified | gnomAD frequency | Count in internal control | Clinical significance/Associated OMIM Syndromes |
|----|---------------------------------------------------------|----------|---------------|--------------------|-----------------|--------------------|----------|-----------------|-------------------|------------------------|-----------------------------------------------|
| C1 | 23-year-old female with progressive social withdrawal on the background of being aloof and slow to warm up with stilted gait. Family history of psychosis in sister | CIC      | NM_01525.3    | chr15:g.21219,2    | G>T             | c.4551G>T          | p.Lys1517 Asn | Het             | NA                | NA                     | VUS Mental retardation, autosomal dominant 45 |
|    |                                                         |          |               |                    |                 |                    |          |                 |                   |                        |                                               |
| C2 | 52-year-old female with schizophrenia (deficit state), family history of similar gradual behavioral decline in mother and paranoid symptoms in the brother | ABCD1    | NM_000033     | chr2:20911010      | G>A             | c.4476G>A          | p.Ala100 Thr  | Het             | NA                | NA                     | VUS 1. Adrenoleukodystrophy 2. Adrenomyeloneuropathy |
|    |                                                         |          |               |                    |                 |                    |          |                 |                   |                        |                                               |
| C3 | 31-year-old male with co-morbid obsessive-compulsive disorder and schizoaffective disorder on the background of Autism Spectrum Disorder, family history of delusional disorder in the first cousin | ATP8A2   | NM_016529.4   | chr13:26343230     | C>T             | c.2431C>T          | p.Arg811 Trp  | Het             | NA                | NA                     | VUS Cerebellar ataxia, mental retardation, and dys equilibrium syndrome 4 |
|    |                                                         |          |               |                    |                 |                    |          |                 |                   |                        |                                               |
| D1 | 33-year-old male with developmental delay along with seizures in childhood presented with progressive regression of milestones from adolescence along with repetitive stereotypical behaviors in adulthood | GARS     | NM_002047.2   | chr7:30671091      | C>T             | c.1855C>T          | p.Leu621 Phe  | Het             | NA                | NA                     | VUS 1. Charcot-Marie-Tooth disease, type 2D 2. Distal spinal muscular atrophy, type V (dSMAV) |
| D2 | 58-year-old male with features of severe Parkinson’s disease with onset in the 5th decade. Symptoms of depression. Family history of a similar illness in father |          |               |                    |                 |                    |          |                 |                   |                        |                                               |

Het: Heterozygous; Hom: Homozygous; LP: Likely Pathogenic; VUS: Variant of Uncertain Significance; NA: Not available.

* This patient was tested for mutations in all 79 exons of the dystrophin gene using multiplex ligation-dependent probe amplification (MLPA). The patient shows deletion of the DMD gene involving exons 45-48. As per the Leiden muscular dystrophy pages the deletion is an in-frame deletion and likely to be a case of Becker muscular dystrophy.
parents had features of inattention, hyperactivity and impulsivity, oppositional behavior, and conduct symptoms, from early childhood. A family history of major depression and anankastic personality traits in a parent and schizophrenia-like illness in a grandparent were noted. On examination, a body mass index of 38 kg/m² and multiple cafe-au-lait spots (five measuring more than 2 cm in diameter), trichilemmoma in the chest, and axillary/inguinal freckling were seen. Blood investigations revealed high total cholesterol and LDL cholesterol but were otherwise unremarkable. The diagnoses of obsessive-compulsive-disorder (OCD), attention deficit hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder in the home context, neurofibromatosis type 1 (NF1), and metabolic syndrome were made. Treatment with lithium (1050 mg/day), escitalopram (40 mg/day), and chlorpromazine (50 mg/day) was initiated.

**Variant(s) in the Gene(s) Not Directly Implicated in Disease But Suspected to Be of Biological Significance: Case C1**

**Clinical Presentation**

A 23-year-old female presented with gradual behavior change, from the age of 15 years, characterized by decreased social interaction, occasional smiling to self, ambivalence, lack of interest toward any activities, feelings of depersonalization, and, eventually, poor self-care and severe neglect. There was no history suggestive of delusions, hallucinations, or pervasive mood changes, and no significant medical history. There was a family history of psychosis and completed suicide in both a sibling and an aunt. There was also a history of multiple first trimester abortions in the mother. Developmental milestones were attained at the appropriate age, but the academic performance was poor from middle school, and significant help was required from the parents to complete assignments. Predominantly, the parents related a history of excessive grooming, a well-established phenotype of OCD in model systems. The downstream effect of NF1 relies upon signaling proteins; GTP-bound forms of these proteins act as molecular switches, turning on downstream effectors. One such GTP-based “switching system” commonly used in cells is the Rho signaling pathway. This patient also has a variant detected in the TRIO gene that encodes a GDP-GTP exchange factor in this particular signaling pathway. The TRIO gene is also associated with neurodevelopmental phenotypes, such as ID and ASD.

The case highlights the complex phenotypes associated with NF1 gene mutations and raises the possibility of multigenic contributions to the final disease manifestation.

**Discussion**

The cases described highlight the diverse contexts where genetic testing may be
ordered in clinical psychiatry. Targeted sequencing is intended to detect rare, possible pathogenic variants in genes already linked to disease. The classification of variants is based on American College of Medical Genetics and Genomics guidelines, which define variants as pathogenic, benign, or of uncertain significance. These guidelines do caution that the "variant category does not imply 100% certainty" and that these may be reclassified as more data accumulates. Given that our understanding of rare variant contributions to psychiatric disorders is evolving, it may be useful to report plausible links to disease syndromes.

We detected rare, possibly damaging variants in several instances, which raise several interesting issues on gene defects and their downstream biology. In Case A1, the rare variant was in the MAPT gene, a well-established genetic link to FTD. The presence of NF1 gene mutation detected in Case B1 adds to the complex array of symptoms already reported with these mutations. It even suggests using statins (lower RAS activity) to target repetitive behaviors in individuals with neurofibromatosis and autism.

Case A3 exemplifies the coexistence of schizophrenia and Becker’s muscular dystrophy (BMD; MIM #300376), which has been occasionally observed. In this person, the deletion is in the distal part of the DMD gene involving exons 45-48, which are part of the brain-expressed isoform. Consequently, the dystrophin protein expressed in different parts of the brain would be impacted, contributing to the neuropsychiatric syndrome. Interestingly, Dp 140 is expressed in the fetal stage and may also have a neurodevelopmental role.

In another person (Case B3), a mutation was detected in the OPAL gene (MIM #605290), which has been associated with parkinsonism and dementia along with chronic progressive external ophthalmoplegia. However, for this case, the monozygotic twin also harbored the same variant but was not symptomatic; hence the role of this variant needs to be interpreted with caution. A person who presented with features of deficit schizophrenia (Case C2) showed a variant in ABCD1 (MIM #300100), which has been associated with X-linked adrenoleukodystrophy (MIM #300100). The mother had a similar deficit state, but the brother had a history of paranoid symptoms. Attenuated behavioral symptoms in females and more severe symptoms, including psychotic symptoms, in males are known to occur in X-linked adrenoleukodystrophy. Another individual (Case B4), who developed progressive supranuclear palsy (PSP) variant of PD on the background of long-standing schizophrenia, had a mutation in the TENM4 gene (MIM *600084). Missense mutations in this gene have been recently implicated as possible candidates for schizophrenia in a Han Chinese population in both familial and sporadic cases. Missense mutations are also associated with essential tremor, but the relation to PD/PSP variant is hitherto unknown.

It must be noted that in two persons (Cases D1 and D2), no variants were found that could contribute to the phenotype, despite a high index of suspicion based on family history and rapid disease progression, highlighting that widespread diagnostic testing for psychiatric conditions is not recommended.

Conclusion

There are several ways that genetic factors can shape the phenotype in those diagnosed with a psychiatric disorder. We suggest that NGS techniques can be a helpful addition when there are expediting factors to consider, such as an early onset, strong family history of mental illness, complex/atypical presentations, and minor physical anomalies or neurocutaneous markers. Most importantly, they provide novel insights into disease biology that can further elucidate the mechanisms underlying psychiatric syndromes.

Acknowledgments

We would like to acknowledge CSIR Institute of Genomics and Integrative Biology, New Delhi where clinical exome sequencing for one of the cases has been performed.

Ethical Statement

Written informed consent was obtained from the patient or their caregiver for publication of this case report at the time of sample collection for targeted sequencing.

Declaration of Conflicting Interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

Salary support for RS, RKN, AGS, and PP was provided by the Accelerator program for Discovery in Brain disorders using Stem cells.

Supplemental Material

Supplemental material for this article is available online.

ORCID IDs

Jayant Mahadevan https://orcid.org/0000-0001-7494-9380
Ravi Kumar Nadella https://orcid.org/0000-0001-5602-945X

References

1. Sanders SJ, Sahin M, Hostyk J, et al. A framework for the investigation of rare genetic disorders in neuropsychiatry. Nat Med 2019; 25: 1477–1487.
2. Vissers LELM, Gilissen C, and Veltman JA. Genetic studies in intellectual disability and related disorders. Nat Rev Genet 2016; 17: 9–18.
3. Hirotta T, Deserno M, and McElroy E. The network structure of irritability and aggression in individuals with autism spectrum disorder. J Autism Dev Disord 2020; 50: 1210–1220.
4. van Duijn E, Kimga E M, and van der Mast R C. Psychopathology in verified Huntington’s disease gene carriers. J Neuropsychiatry Clin Neurosci 2007; 19: 441–448.
5. Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol 2017; 13: 81–95.
6. Ganesh S, Ahmed PH, Nadella RK, et al. Exome sequencing in families with severe mental illness identifies novel and rare variants in genes implicated in Mendelian neuropsychiatric syndromes. Psychiatry Clin Neurosci 2019; 73: 11–19.
7. Maher MC, Uricchio LH, Torgerson DG, et al. Population genetics of rare variants and complex diseases. Hum Hered 2012; 74: 118–128.
8. He S, Chen S, Xia M-R, et al. The role of MAPT gene in Chinese dementia patients: a P301L pedigree study and brief literature review. Neuropsychiatr Dis Treat 2018; 14: 1627–1633.
9. Strang KH, Golde TE, and Giasson BI. MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Lab Invest 2019; 99: 912–928.
10. Guo JL and Lee VM-Y. Seeding of normal Tau by pathologival Tau conformers drives pathogenesis of Alzheimer-like tangles. J Biol Chem 2011; 286: 15317–15331.
11. Daude N, Kim C, Kang S-G, et al. Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation. Acta Neuropathol 2020; 139: 1045–1070.

12. Gutmann DH, Ferner RE, Listerick RH, et al. Neurofibromatosis type 1. Nat Rev Dis Primers 2017; 3: 17004.

13. King LB, Koch M, Murphy KR, et al. Neurofibromin loss of function drives excessive grooming in Drosophila. G3 (Bethesda) 2016; 6: 1083–1093.

14. Szechtman H, Ahmari SE, Beninger RJ, et al. Obsessive-compulsive disorder: Insights from animal models. Neurosci Biobehav Rev 2017; 76: 254–279.

15. Katrancha SM, Wu Y, Zhu M, et al. Neurodevelopmental disease-associated de novo mutations and rare sequence variants affect TRIO GDP/GTP exchange factor activity. Hum Mol Genet 2017; 26: 4728–4740.

16. Lu H-C, Tan Q, Rousseaux MW, et al. Disruption of the ATXN1–CIC complex causes a spectrum of neurobehavioral phenotypes in mice and humans. Nat Genet 2017; 49: 527.

17. Butler MG. Clinical and genetic aspects of the 15q11.2 BP1–BP2 microdeletion disorder. J Intellect Disabil Res 2017; 61: 568–579.

18. Murthy SK, Nygren AOH, El Shakankiry HM, et al. Detection of a novel familial deletion of four genes between BP1 and BP2 of the Prader-Willi/Angelman syndrome critical region by oligo-array CGH in a child with neurological disorder and speech impairment. Cytogenet Genome Res 2007; 116: 135–140.

19. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405–424.

20. Boycott KM, Hartley T, Biesecker LG, et al. A Diagnosis for All Rare Genetic Diseases: The Horizon and the Next Frontiers. Cell 2019; 177: 32–37.

21. Molosh AI and Shekhar A. Neurofibromatosis type 1 as a model system to study molecular mechanisms of autism spectrum disorder symptoms. In: Progress in brain research. Elsevier, 2018, pp. 37–62.

22. Mori-Yoshimura M, Mizuno Y, Yoshida S, et al. Psychiatric and neurodevelopmental aspects of Becker muscular dystrophy. Neuromuscul Disord 2019; 29: 930–939.

23. Deepa S, Vengalil S, Preeadh-Kumar V, et al. MLPA identification of dystrophin mutations and in silico evaluation of the predicted protein in dystrophinopathy cases from India. BMC Med Genet 2017; 18: 67.

24. Carelli V, Musumeci O, Caporali L, et al. Syndromic parkinsonism and dementia associated with OPA1 missense mutations. Ann Neurol 2015; 78: 21–38.

25. Foschi M, Vacchiano V, Avoni P, et al. Broadening the Spectrum of Adulthood X-Linked Adrenoleukodystrophy: A Report of Two Atypical Cases. Front Neurol 2019; 10: 70.

26. Xue C-B, Xu Z-H, Zhu J, et al. Exome Sequencing Identifies TENM4 as a Novel Candidate Gene for Schizophrenia in the SCZD2 Locus at 11q14-21. Front Genet 2018; 9: 725.

27. Hor H, Francescatto L, Bartesaghi L, et al. Missense mutations in TENM4, a regulator of axon guidance and central myelination, cause essential tremor. Hum Mol Genet 2015; 24: 5677–5686.